Gene Logic, Inc. and Organon have entered into a drug repositioning agreement to seek alternative development paths for multiple drug candidates of which Organon previously discontinued clinical development. Under the terms of the agreement, Gene Logic will seek new therapeutic uses for Organon compounds. Upon discovery of potential new therapeutic utility, both companies will become equal owners and may decide to jointly develop and commercialize the drug candidate. Gene Logic will receive...